

Supplementary Table S4. Summary of results

End point	Primary analysis (cutoff: February 29, 2012)		OS analysis (cutoff: June 30, 2014)	
	[15]			
	Chemotherapy alone (<i>N</i> = 1290)	Chemotherapy + bevacizumab (<i>N</i> = 1301)	Chemotherapy alone (<i>N</i> = 1290)	Chemotherapy + bevacizumab (<i>N</i> = 1301)
Median duration of follow-up, months	31.5	32.0	56.0	56.0
IDFS	Primary		Exploratory	
Events, <i>N</i> (%)	205 (15.9)	188 (14.5)	270 (20.9)	244 (18.8)
Stratified HR (95% CI)	0.87 (0.72–1.07)		0.87 (0.73–1.03)	
Log-rank <i>P</i> value	0.18		0.11	

3-year IDFS rate, % (95% CI)	82.7 (80.5–85.0)	83.7 (81.4–86.0)	82.8 (80.7–84.9)	84.6 (82.6–86.6)
OS	Interim		Final	
Events, <i>N</i> (%)	107 (8.3)	93 (7.1)	149 (11.6)	144 (11.1)
Stratified HR (95% CI)	0.84 (0.64–1.12)		0.93 (0.74–1.17)	
Log-rank <i>P</i> value	0.23		0.52	

CI, confidence interval; HR, hazard ratio; IDFS, invasive disease-free survival; OS, overall survival.
